GB9520615D0 - Method of preventing bone loss - Google Patents

Method of preventing bone loss

Info

Publication number
GB9520615D0
GB9520615D0 GBGB9520615.7A GB9520615A GB9520615D0 GB 9520615 D0 GB9520615 D0 GB 9520615D0 GB 9520615 A GB9520615 A GB 9520615A GB 9520615 D0 GB9520615 D0 GB 9520615D0
Authority
GB
United Kingdom
Prior art keywords
bone loss
preventing bone
preventing
loss
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB9520615.7A
Other versions
GB2294879A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of GB9520615D0 publication Critical patent/GB9520615D0/en
Publication of GB2294879A publication Critical patent/GB2294879A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB9520615A 1994-10-19 1995-10-09 Cylcooxygenase-2 Inhibitors Withdrawn GB2294879A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32575994A 1994-10-19 1994-10-19

Publications (2)

Publication Number Publication Date
GB9520615D0 true GB9520615D0 (en) 1995-12-13
GB2294879A GB2294879A (en) 1996-05-15

Family

ID=23269329

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9520615A Withdrawn GB2294879A (en) 1994-10-19 1995-10-09 Cylcooxygenase-2 Inhibitors

Country Status (2)

Country Link
US (1) US5663195A (en)
GB (1) GB2294879A (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
WO1999023087A1 (en) * 1997-10-30 1999-05-14 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2(5h)-furanones as selective cyclooxygenase-2 inhibitors
US6133292A (en) * 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
CA2347768A1 (en) * 1998-10-27 2000-05-04 Merck & Co., Inc. Synthesis of methylthiophenyl hydroxyketones
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
WO2000028982A2 (en) 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
EP2095817A1 (en) * 1999-12-07 2009-09-02 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
AR038957A1 (en) 2001-08-15 2005-02-02 Pharmacia Corp COMBINATION THERAPY FOR CANCER TREATMENT
NZ532064A (en) * 2001-10-10 2006-04-28 Pharmacia Italia Spa Methods for preventing and treating bone loss with steroid compounds
EP1446009A2 (en) * 2001-11-08 2004-08-18 Merck & Co., Inc. Compounds useful in the treatment of anthrax
US20040053968A1 (en) * 2001-12-28 2004-03-18 Hartman George D. Methods and compositions for treating peridontal disease
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
ES2213485B1 (en) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. DERIVATIVES OF 2-FENILPIRAN-4-ONA.
WO2005027918A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a cyclooxgenase-2 inhibitor
US20050244499A1 (en) * 2004-05-03 2005-11-03 Robert Diaz Method and device for reducing susceptibility to fractures in long bones
US20050244451A1 (en) * 2004-05-03 2005-11-03 Robert Diaz Method and device for reducing susceptibility to fractures in vertebral bodies
US20060089642A1 (en) * 2004-10-27 2006-04-27 Diaz Robert L Prefracture spinal implant for osteoporotic unfractured bone
US20070167510A1 (en) * 2006-01-13 2007-07-19 Suzanne Lentzsch Methods for inhibiting osteoclastogenesis
CN101801188A (en) 2007-07-12 2010-08-11 特拉加拉医药品公司 Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
SG11201507445VA (en) * 2013-03-15 2015-10-29 Theocorp Holding Company Llc Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3519361A1 (en) * 1985-05-30 1986-12-04 Boehringer Ingelheim International GmbH, 6507 Ingelheim (GAMMA) -IFN AS AN ACTIVE SUBSTANCE FOR INHIBITING (PREVENTING) DEGREASING PROCESSES IN THE BONE
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
WO1994015932A1 (en) * 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
AU6718494A (en) * 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
AU692231B2 (en) * 1994-02-10 1998-06-04 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation

Also Published As

Publication number Publication date
US5663195A (en) 1997-09-02
GB2294879A (en) 1996-05-15

Similar Documents

Publication Publication Date Title
GB9520615D0 (en) Method of preventing bone loss
EP0771203A4 (en) Method of treating sweat-related conditions
PL333364A1 (en) Novel compounds and method of using them
ZA977564B (en) Method of treatment
PL318452A1 (en) Method of obtaining peroxyperfluoropolyoxyalkylenes
PL330400A1 (en) Method of obtaining azacyclohexapeptides
PL320699A1 (en) Method of obtaining cephotaxime
AU6883398A (en) Methods of treating bone loss
PL332077A1 (en) Method of obtaining omepraole
PL313419A1 (en) Method of obtaining beta-naphtole
ZA973988B (en) Method of treatment
GB9618341D0 (en) Method of treatment
PL333977A1 (en) Method of obtaining benzisothiazolyn-3-ones
PL310540A1 (en) Method of obtaining sulphur
PL306900A1 (en) Method of obtaining 1-amino-1-methylo-3(4)-cyano-cyclohexane
GB9415902D0 (en) Method of treatment
PL317788A1 (en) Method of obtaining 3-isocyanate-propylsilane
PL332075A1 (en) Method of obtaining nizathidine
GB9407335D0 (en) Method of treatment
PL301929A1 (en) Method of obtaining epichlorohydine
GB9604739D0 (en) Surgical method
GB9414652D0 (en) Method of treatment
GB9420524D0 (en) Method of treatment
PL306637A1 (en) Method of obtaining (e)-3-methyl-6-trimethylsilisium 4-hexen-1-ol
PL304106A1 (en) Method of obtaining saccharose-modified cofffee

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)